GlassScriptPhysician profile
Zenowij Majuk
NPI 1851376297
$8,294.20
in general payments reported to CMS, 2019-2025
31 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,396 · 2020: $847 · 2021: $1,603 · 2022: $1,140 · 2023: $917 · 2024: $1,038 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,176 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,175.96 |
| Education | $132.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,900.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $982.21 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $901.59 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $784.84 | 2020-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $695.02 | 2020-2023 | |
| Pfizer INC. | $354.11 | 2019-2024 | |
| Braintree Laboratories, INC. | $308.58 | 2019-2025 | Suflave, Sutab |
| Celltrion USA INC. | $302.42 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Romark Laboratories, Lc | $256.83 | 2019-2020 | |
| Allergan, INC. | $227.53 | 2019 | |
| Qol Medical, LLC | $222.32 | 2022-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $171.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $165.48 | 2019-2022 | |
| Vivus LLC | $139.45 | 2019-2025 | Pancreaze, Qsymia |
| Gilead Sciences, INC. | $137.18 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $134.69 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $98.29 | 2019-2024 | |
| Celgene Corporation | $89.37 | 2021-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $66.85 | 2022 | |
| Aimmune Therapeutics, INC. | $62.36 | 2023-2024 | |
| Biocon Biologics INC | $52.04 | 2024 | Hulio |
| Madrigal Pharmaceuticals | $37.79 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $32.30 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $28.02 | 2023 | Dupixent |
| Daiichi Sankyo INC. | $26.88 | 2019 | |
| Alfasigma USA, INC. | $25.69 | 2021 | |
| Ironwood Pharmaceuticals, INC | $23.57 | 2021 | |
| Lilly USA, LLC | $22.08 | 2023 | |
| Echosens North America, INC. | $18.74 | 2024 | Fibroscan |
| Phathom Pharmaceuticals, INC. | $18.55 | 2025 | Voquezna |
| Ambu INC. | $8.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zenowij Majuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.